Fibrodysplasia ossificans progressiva (FOP) is a rare disease characterized by extensive bone growth outside of the normal skeleton that pre-empts the body's normal responses to even minor injuries.

BELLMAWR, New Jersey (WPVI) -- A young South Jersey boy has one wish for his birthday this year, and that is to help raise money for those living with a rare disease. Nine-year-old AJ Gonzales of ...

The Independent Data Monitoring Committee recommended transitioning patients in the placebo arm to garetosmab as soon as possible. Topline data were announced from a phase 3 trial evaluating ...

PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN: ADR: IPSEY) today announced that it will share data from the company’s growing Rare Diseases Therapeutic Area portfolio, with seven ...

PARIS, FRANCE, 19 December 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the pivotal Phase II FALKON trial did not meet its primary endpoint of reducing new heterotopic ossification ...

Ipsen to request re-examination of CHMP opinion on palovarotene as a potential treatment for fibrodysplasia ossificans progressiva in E.U. FOP is an ultra-rare disease that continuously and ...

FOP is a disease in which muscles, tendons and ligaments are progressively replaced by bone, leading to eventual incapacitation Garetosmab is the first and only treatment to demonstrate a dramatic ...

A mutation in the gene that causes fibrodysplasia ossificans progressiva (FOP) doesn't just cause extra bone growth but is tied to a problem in generating new muscle tissue after injury, according to ...